Background/aim S-1, a 5-fluorouracil(5-FU) oral anti-cancer drug, has been traditionally used with schedule of 4-week administration followed by 2-week rest for breast cancer treatment. We, herein, aimed to investigate the clinical efficacy and safety 1-week patients metastatic cancer. Patients methods We enrolled HER2-negative who had not received prior chemotherapy. S-1 was administered conse...
